Physician profile
Nancy Guttman
NPI 1477551596
$2,718.23
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $516 · 2021: $691 · 2022: $533 · 2023: $581 · 2024: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $868.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $717.56 | 2021-2024 | |
| Allergan, INC. | $229.39 | 2019-2021 | |
| Glaxosmithkline, LLC. | $196.67 | 2019-2024 | Trelegy Ellipta |
| Corcept Therapeutics | $148.43 | 2023 | Korlym |
| Astellas Pharma US INC | $132.38 | 2020-2021 | |
| Novo Nordisk INC | $128.81 | 2020-2023 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $116.13 | 2019-2022 | |
| Amarin Pharma, INC. | $109.24 | 2020-2021 | |
| Lilly USA, LLC | $101.61 | 2019-2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $96.63 | 2021-2024 | |
| Esperion Therapeutics, INC. | $70.01 | 2021-2022 | |
| Exact Sciences Corporation | $67.51 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $67.07 | 2019-2022 | |
| Ibsa Pharma INC. | $58.79 | 2021-2023 | Tirosint, Licart |
| Mannkind Corporation | $57.67 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $51.88 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $39.20 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $37.02 | 2021-2023 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $34.52 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $34.11 | 2019-2020 | |
| Abbott Laboratories | $33.89 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $31.78 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $25.72 | 2023 | Auvelity |
| Merck Sharp & Dohme LLC | $23.85 | 2020 | |
| Supernus Pharmaceuticals, INC. | $19.88 | 2023 | Qelbree |
| Biogen, INC. | $17.67 | 2021 | |
| Qol Medical, LLC | $16.04 | 2023 | Sucraid |
| Alexion Pharmaceuticals, INC. | $15.47 | 2023 | Strensiq |
| Vanda Pharmaceuticals INC. | $15.10 | 2022 | |
| Medtronic, INC. | $12.43 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Guttman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.